V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214265 | 20080585 | 1.81 | 69.2 | Palliative (P) | 2019-07-05 | 2019-07-23 | Imatinib 400mg | 02 | N | IMATINIB | 100611996 |
| 20214266 | 20080586 | null | 40.8 | Curative (C) | 2016-05-08 | 2016-06-04 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100597620 |
| 20214268 | 20080587 | 1.7 | 76.7 | Palliative (P) | null | 2018-10-10 | null | null | N | TRIAL | 101005444 |
| 20214269 | 20080588 | 1.78 | 65 | Palliative (P) | 2016-07-22 | 2016-08-04 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100038495 |
| 20214270 | 20080589 | 0 | 77 | Palliative (P) | 2017-01-14 | 2017-01-28 | LANREOTIDE | null | N | LANREOTIDE | 101201821 |
| 20214271 | 20080590 | 0 | 48.5 | Palliative (P) | 2017-03-05 | 2017-03-12 | HCX (Cape + Cisp + Tras) - Load | null | N | LANREOTIDE | 100854519 |
| 20214272 | 20080591 | 1.68 | 98.1 | null | 2018-03-04 | 2018-03-09 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 100271370 |
| 20214273 | 20080592 | 1.54 | 70.6 | Palliative (P) | 2018-07-02 | 2018-07-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101018681 |
| 20214274 | 20080593 | 1.5 | 63 | Palliative (P) | 2019-10-18 | 2019-11-05 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101550365 |
| 20214275 | 20080594 | 1.85 | 103.3 | Palliative (P) | 2016-06-28 | 2016-07-12 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101076331 |
| 20214276 | 20080595 | 1.7 | 66 | Curative (C) | 2018-03-08 | 2018-03-24 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100885936 |
| 20214277 | 20080596 | 1.59 | 76.3 | null | 2019-02-13 | 2019-03-27 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 101053354 |
| 20214278 | 20080597 | 1.66 | 0 | Palliative (P) | 2016-12-07 | 2016-12-14 | Trial Unspecified | 1 | N | TRIAL | 101800908 |
| 20214279 | 20080598 | 1.55 | 87 | null | 2018-04-22 | 2018-04-27 | IMATINIB | 02 | null | IMATINIB | 101217445 |
| 20214280 | 20080599 | 1.71 | 69.9 | Palliative (P) | 2016-04-15 | 2016-04-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101103973 |
| 20214282 | 20080600 | 1.75 | 46.8 | Curative (C) | 2017-03-10 | 2017-03-14 | FLUOROURACIL + MITOMYCIN + RT | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101299740 |
| 20214284 | 20080601 | 1.89 | 79 | Palliative (P) | 2016-11-20 | 2016-12-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101471835 |
| 20214286 | 20080602 | 0 | null | Neo-adjuvant (N) | 2016-05-01 | 2016-05-23 | Imatinib 400mg | 02 | N | IMATINIB | 100997059 |
| 20214287 | 20080603 | 1.61 | 76.3 | Palliative (P) | 2017-10-10 | 2017-10-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101290414 |
| 20214288 | 20080604 | 1.63 | 63.1 | Curative (C) | null | 2018-10-03 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101555329 |
| 20214289 | 20080605 | 1.6 | 66.7 | null | 2018-05-23 | 2018-05-23 | Imatinib 400mg | 02 | null | IMATINIB | 100001590 |
| 20214290 | 20080606 | 1.7 | 72.2 | Palliative (P) | 2020-05-14 | 2020-05-18 | GO2 TRIAL | 1 | N | TRIAL | 100471956 |
| 20214294 | 20080608 | 1.72 | 50.1 | Palliative (P) | 2018-04-22 | 2018-05-05 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101684916 |
| 20214295 | 20080609 | 1.49 | 62 | Adjuvant (A) | 2019-07-21 | 2019-08-01 | Trial Unspecified | Y | N | TRIAL | 100051403 |
| 20214297 | 20080611 | 1.74 | 86 | Curative (C) | null | 2017-11-26 | FLUOROURACIL + MITOMYCIN + RT | N | null | FLUOROURACIL + MITOMYCIN + RT | 100053735 |
| 20214298 | 20080612 | 0 | 58.1 | null | 2017-11-12 | 2017-12-18 | LANREOTIDE | 02 | null | LANREOTIDE | 100468568 |
| 20214299 | 20080613 | 1.63 | 61.7 | Curative (C) | 2018-09-15 | 2018-09-29 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100995482 |
| 20214300 | 20080614 | 1.69 | 74 | Palliative (P) | 2021-02-20 | 2021-02-28 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101477520 |
| 20214301 | 20080615 | 1.68 | 80 | Palliative (P) | 2019-09-20 | 2019-09-20 | Trial Unspecified | 01 | N | TRIAL | 100449828 |
| 20214302 | 20080616 | 0 | 72.3 | Palliative (P) | 2018-02-18 | 2018-03-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101047594 |
| 20214304 | 20080617 | 1.65 | 65 | Curative (C) | 2016-06-23 | 2016-07-29 | FLUOROURACIL + MITOMYCIN + RT | N | N | FLUOROURACIL + MITOMYCIN + RT | 100361010 |
| 20214305 | 20080618 | 1.8 | 58.05 | Palliative (P) | 2016-12-10 | 2016-12-10 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100914794 |
| 20214306 | 20080619 | 1.65 | 67 | Palliative (P) | 2018-04-10 | 2018-04-11 | IMATINIB | 02 | N | IMATINIB | 101707879 |
| 20214307 | 20080620 | 1.6 | 113 | Curative (C) | 2017-03-16 | 2017-04-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101363006 |
| 20214309 | 20080621 | 1.61 | 55 | Palliative (P) | 2018-01-02 | 2018-01-23 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100648131 |
| 20214311 | 20080622 | 0 | 103.35 | Neo-adjuvant (N) | 2019-05-01 | 2019-05-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101167149 |
| 20214312 | 20080623 | 1.7 | 83 | Curative (C) | 2017-12-21 | 2017-12-29 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100204914 |
| 20214313 | 20080624 | 1.69 | 83.25 | Palliative (P) | 2016-06-21 | 2016-06-29 | GO2 TRIAL | 01 | N | TRIAL | 101019397 |
| 20214314 | 20080625 | 1.53 | 82.35 | null | 2019-01-02 | 2019-01-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 100678502 |
| 20214315 | 20080626 | 1.71 | 68.3 | Curative (C) | 2017-12-21 | 2018-01-19 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101861415 |
| 20214316 | 20080627 | 1.61 | 61.7 | Palliative (P) | 2017-01-25 | 2017-02-01 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101304733 |
| 20214317 | 20080628 | 1.8 | 49 | null | 2016-11-14 | 2016-11-16 | Imatinib 400mg | 02 | null | IMATINIB | 101138191 |
| 20214318 | 20080629 | 1.74 | 69.2 | Palliative (P) | 2020-02-22 | 2020-04-06 | LANREOTIDE | 02 | N | LANREOTIDE | 101380634 |
| 20214319 | 20080630 | 1.86 | 100.8 | Curative (C) | 2019-02-09 | 2019-03-05 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101152431 |
| 20214320 | 20080631 | 1.65 | 86 | Palliative (P) | 2019-07-20 | 2019-07-20 | Imatinib 400mg | 02 | N | IMATINIB | 101082200 |
| 20214321 | 20080632 | 1.62 | 51 | Palliative (P) | null | 2016-06-13 | Cetuximab + FLUOROURACIL + IRINOTECAN | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100499673 |
| 20214322 | 20080633 | 1.67 | 0 | Palliative (P) | 2019-04-15 | 2019-04-16 | Imatinib 400mg | 02 | N | IMATINIB | 100682679 |
| 20214323 | 20080634 | 1.82 | 95.6 | Palliative (P) | 2017-08-12 | 2017-08-19 | Trial Unspecified | Y | N | TRIAL | 100521178 |
| 20214325 | 20080635 | 1.56 | 82.35 | Palliative (P) | 2018-05-19 | 2018-06-15 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101816293 |
| 20214326 | 20080636 | 1.62 | 107 | Curative (C) | 2018-02-05 | 2018-04-07 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101082702 |